Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast will ...

EY—the professional services firm originally known as Ernst & Young—reports the dollar value of biopharma M&A deals nosedived ...

Vertex Pharmaceuticals' suzetrigine showed lackluster ... The FDA, in my opinion, will continue to support the development of non-addictive pain medication given the opioid crisis the world ...

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more ...

Jason Kim has been appointed chief financial officer at Enveda Biosciences, a biotechnology company using artificial ...

Cramer likes Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and highlighted the company’s catalysts, including its non-opioid painkillers that are under development. “Oh, next, how about ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq ... Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia ...